The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.c

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

Publications

DUSTAN HP, TAYLOR RD, CORCORAN AC

Rheumatic and febrile syndrome during prolonged hydralazine treatment.

Journal of the American Medical Association. 1954;154(1):23-9

Peacock A, Weatherall D

Hydralazine-induced necrotising vasculitis.

British medical journal (Clinical research ed.). 1981;282(6270):1121-2

Martinez-Vea A, Ferrer I, Carcía C, Mayayo E, Oliver JA, Richart C

Systemic vasculitis resembling periarteritis nodosa in the lupus-like syndrome induced by hydralazine.

American journal of nephrology. 1987;7(1):71-3